Fluidigm price target raised to $47 from $28 at Cantor Cantor increased its price target on Fluidigm after the company acquired privately held DVS Sciences. The firm thinks the deal further strengthens and diversifies Fluidigm's already highly capabilities in single-cell genomics, and leaves the company better positioned to accelerate market expansion for single-cell analysis. The firm keeps a Buy rating on the stock.
News For FLDM From The Last 14 Days
Check below for free stories on FLDM the last two weeks.
Fluidigm upgraded to Outperform from Market Perform at Leerink Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.
Piper Jaffray's medtech analysts hold an analyst/industry conference call The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.